Meloxicam sustained release tablet used for pet and preparation method thereof

A technology of meloxicam and sustained-release tablets, which is applied in the field of meloxicam sustained-release tablets for pets and its preparation, can solve the problems of large influence on the therapeutic effect, excessive fluctuation of blood drug concentration, and dissolution rate of meloxicam. Low-level problems, to achieve the effect of improving clinical treatment effect, reducing the risk of injury, and easy to expand production

Active Publication Date: 2014-04-09
RINGPU TIANJIN BIOLOGICAL PHARMA
View PDF5 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The patent (CN1708307B, published on December 7, 2011) provides a water-soluble granule containing meloxicam, which is mainly composed of meloxicam, meglumine, sugar, povidone, etc. The main advantage is to enhance the meloxicam The water solubility and palatability of Xicam facilitate clinical administration, but there are two disadvantages: first, the dosage is inaccurate; second, frequent administration can easily cause excessive fluctuations in blood drug concentration, which is harmful to clinical treatment. The effect of treatment is greater
The patent (CN102525974A, published on July 4, 2012) provides a meloxicam tablet for dogs and cats and its preparation method, which mainly consists of meloxicam, lactose, microcrystalline cellulose, hydroxypropyl cellulose, sodium citrate , cross-linked polyvinylpyrrolidone, pvpK30, aspartame, magnesium stearate, the main advantage is to reduce the gastrointestinal irritation, the disadvantages are: 1. The dissolution rate of meloxicam is low, which is not conducive to absorption; 2. poor palatability

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Meloxicam sustained release tablet used for pet and preparation method thereof
  • Meloxicam sustained release tablet used for pet and preparation method thereof
  • Meloxicam sustained release tablet used for pet and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Party:

[0022]

[0023] Preparation:

[0024] A, firstly prepare the solid dispersion of meloxicam and meglumine, dissolve meloxicam and meglumine in water together, carry out vacuum drying, pulverize the dried solid powder, pass through a 200 mesh sieve, spare;

[0025] B, the meloxicam solid dispersion after sieving, sustained and controlled release auxiliary material, filler, 80% flavoring agent and 30% binding agent mix homogeneously;

[0026] C. Add the ethanol / water (30 / 70) solution of the remaining 70% of the adhesive and mix evenly to make a soft material;

[0027] D. Carry out wet granulation of the prepared soft material, dry at 60°C for 1 hour, and granulate;

[0028] E, add lubricant and remaining 20% ​​correctives to the prepared granule and mix evenly;

[0029] F, tablet pressing, finished product.

Embodiment 2

[0030] Embodiment 2 stability test

[0031] 1 Materials and methods

[0032] 1.1 Material test drugs: meloxicam sustained-release tablets prepared according to Example 1-A, Example 1-B, and Example 1-C respectively; control drugs: according to the patent (CN102525974A, issued on July 4, 2012 Published in Japan) self-made meloxicam tablets with a content of 0.2mg.

[0033] 1.2 Methods Take 180 tablets of the test drug and the control drug respectively. According to the "Technical Specifications for Stability Test of Veterinary Drugs (Trial)", the accelerated test of the drug was carried out for six months. Sampling for content determination.

[0034] 2 Test results

[0035] Example 2 Drug Stability Test Results (n=4)

[0036]

[0037] The results show that the drug stability of the meloxicam sustained-release tablets prepared in Example 1-A, Example 1-B, and Example 1-C is obviously better than that of the reference drug. It shows that the preparation is stable.

Embodiment 3

[0038] Example 3 Clinical Trials

[0039] 1. Materials and Methods

[0040] 1.1 Test material

[0041] 1.1.1 Test drug Test drug: Example 1-C, used continuously for seven days; control drug: self-made meloxicam tablets according to the patent (CN102525974A, published on July 4, 2012), with a content of 5 mg.

[0042] 1.1.2 Experimental animals Tianjin Pet Hospital has diagnosed dogs with osteoarthritis, 80 dogs have been diagnosed with the disease, and the age of onset is 9-13 years old.

[0043] 1.2 Test method: Divide 80 naturally occurring dogs into five groups of I, II, III, IV and V, with 16 dogs in each group. Group I is the infection-free group; Group II is the group treated with low-dose test drugs (0.1 mg orally administered per kilogram of body weight for the first time, 0.05 mg for the second dose, once every two days, for 5 consecutive times); Group III is the treatment group with a medium dose of the test drug (0.2 mg orally administered for the first time per k...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a meloxicam sustained release tablet used for a pet and a preparation technology thereof. The meloxicam sustained release tablet is stable to release and safe to administrate and comprises solid meloxicam dispersoid, a sustained release material, a filling material, an adhesive, a lubricant and a corrigent. The meloxicam sustained release tablet has the characteristics of convenient administration, rapid and lasting effects and stable curative effects.

Description

technical field [0001] The invention belongs to the field of veterinary drug preparations, in particular to a meloxicam sustained-release tablet for pets and a preparation method thereof. Background technique [0002] Meloxicam is a new generation of non-steroidal anti-inflammatory drugs developed in the 1990s, mainly for pet dogs and cats. Quinolones anticoccidial drugs, because of their selective inhibition of type Ⅱ cyclooxygenase (COX-2), are the type Ⅱ cyclooxygenase with the least oral gastrointestinal side effects among similar non-steroidal anti-inflammatory drugs Inhibitors also have the advantages of strong anti-inflammatory effect, good antipyretic effect, good and complete oral absorption, high bioavailability, long half-life, less dosage, and no nephrotoxicity. In the pet market, meloxicam also has the advantages of definite curative effect, strong tolerance, and less side effects on the gastrointestinal tract, so it is also favored by clinical veterinarians. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/22A61K31/5415A61P29/00
Inventor 魏德宝张静徐晓然
Owner RINGPU TIANJIN BIOLOGICAL PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap